BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more
BeiGene, Ltd. (ONC) - Net Assets
Latest net assets as of December 2025: $4.36 Billion USD
Based on the latest financial reports, BeiGene, Ltd. (ONC) has net assets worth $4.36 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.19 Billion) and total liabilities ($3.83 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.36 Billion |
| % of Total Assets | 53.26% |
| Annual Growth Rate | N/A |
| 5-Year Change | -28.88% |
| 10-Year Change | 1135.79% |
| Growth Volatility | 132.81 |
BeiGene, Ltd. - Net Assets Trend (2013–2025)
This chart illustrates how BeiGene, Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BeiGene, Ltd. (2013–2025)
The table below shows the annual net assets of BeiGene, Ltd. from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.36 Billion | +30.88% |
| 2024-12-31 | $3.33 Billion | -5.80% |
| 2023-12-31 | $3.54 Billion | -19.30% |
| 2022-12-31 | $4.38 Billion | -28.52% |
| 2021-12-31 | $6.13 Billion | +58.50% |
| 2020-12-31 | $3.87 Billion | +295.48% |
| 2019-12-31 | $978.36 Million | -44.21% |
| 2018-12-31 | $1.75 Billion | +156.29% |
| 2017-12-31 | $684.23 Million | +93.88% |
| 2016-12-31 | $352.91 Million | +374.85% |
| 2015-12-31 | $74.32 Million | +188.42% |
| 2014-12-31 | $25.77 Million | +169.72% |
| 2013-12-31 | $-36.96 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BeiGene, Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 827708800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $144.00K | 0.00% |
| Other Comprehensive Income | $-78.18 Million | -1.79% |
| Other Components | $12.76 Billion | 292.56% |
| Total Equity | $4.36 Billion | 100.00% |
BeiGene, Ltd. Competitors by Market Cap
The table below lists competitors of BeiGene, Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Engie SA
PINK:ENGQF
|
$33.33 Billion |
|
Archer-Daniels-Midland Company
NYSE:ADM
|
$33.40 Billion |
|
Keurig Dr Pepper Inc
NASDAQ:KDP
|
$33.59 Billion |
|
Chunghwa Telecom Co Ltd
NYSE:CHT
|
$33.61 Billion |
|
Hyundai Motor S3 Pref
KO:005389
|
$33.13 Billion |
|
Ingersoll Rand Inc
NYSE:IR
|
$33.10 Billion |
|
HOWMET AEROSPACE 375 PFD
F:48Z0
|
$33.09 Billion |
|
Volvo AB Series A
LSE:0MHW
|
$33.02 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BeiGene, Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,332,222,000 to 4,361,194,000, a change of 1,028,972,000 (30.9%).
- Net income of 286,933,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 70,804,000.
- Other factors increased equity by 671,235,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $286.93 Million | +6.58% |
| Other Comprehensive Income | $70.80 Million | +1.62% |
| Other Changes | $671.24 Million | +15.39% |
| Total Change | $- | 30.88% |
Book Value vs Market Value Analysis
This analysis compares BeiGene, Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-7.35 | $287.33 | x |
| 2014-12-31 | $0.49 | $287.33 | x |
| 2015-12-31 | $-3.23 | $287.33 | x |
| 2016-12-31 | $11.37 | $287.33 | x |
| 2017-12-31 | $16.38 | $287.33 | x |
| 2018-12-31 | $31.63 | $287.33 | x |
| 2019-12-31 | $16.02 | $287.33 | x |
| 2020-12-31 | $46.35 | $287.33 | x |
| 2021-12-31 | $66.09 | $287.33 | x |
| 2022-12-31 | $42.50 | $287.33 | x |
| 2023-12-31 | $33.89 | $287.33 | x |
| 2024-12-31 | $31.65 | $287.33 | x |
| 2025-12-31 | $38.44 | $287.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BeiGene, Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.58%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.37%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 1.88x
- Recent ROE (6.58%) is above the historical average (-31.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -67.22% | 0.94x | 0.00x | $-3.62 Million |
| 2014 | -70.93% | -140.22% | 0.24x | 2.08x | $-20.85 Million |
| 2015 | 0.00% | -647.71% | 0.08x | 0.00x | $-46.93 Million |
| 2016 | -33.78% | -11141.78% | 0.00x | 1.15x | $-154.51 Million |
| 2017 | -13.61% | -39.06% | 0.23x | 1.53x | $-161.53 Million |
| 2018 | -38.42% | -339.91% | 0.09x | 1.28x | $-849.13 Million |
| 2019 | -98.59% | -221.53% | 0.27x | 1.68x | $-1.04 Billion |
| 2020 | -42.00% | -526.10% | 0.06x | 1.45x | $-2.01 Billion |
| 2021 | -23.77% | -123.93% | 0.14x | 1.39x | $-2.07 Billion |
| 2022 | -45.71% | -141.52% | 0.22x | 1.46x | $-2.44 Billion |
| 2023 | -24.93% | -35.86% | 0.42x | 1.64x | $-1.24 Billion |
| 2024 | -19.35% | -16.92% | 0.64x | 1.78x | $-978.01 Million |
| 2025 | 6.58% | 5.37% | 0.65x | 1.88x | $-149.19 Million |
Industry Comparison
This section compares BeiGene, Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BeiGene, Ltd. (ONC) | $4.36 Billion | 0.00% | 0.88x | $33.32 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |